 | |
| Clinical data | |
|---|---|
| Trade names | Ibsrela, Xphozah, others |
| Other names | Tenapanor hydrochloride |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | By mouth |
| Drug class | NHE3 inhibitors |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.243.471 |
| Chemical and physical data | |
| Formula | C50H66Cl4N8O10S2 |
| Molar mass | 1145.04 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Tenapanor, sold under the brand nameIbsrela among others, is amedication used for the treatment of adults with a disease of the gut calledirritable bowel syndrome withconstipation commonly referred to as IBS-C.[3][5] It is used in form of tenapanor hydrochloride.[3] It is also used in the treatment of hyperphosphatemia associated withchronic kidney disease.[4] Tenapanor is a sodium hydrogen exchanger 3 (NHE3) inhibitor.[4]
Tenapanor is a drug developed by Ardelyx, which acts as an inhibitor of thesodium-proton exchanger NHE3. Thisantiporter protein is found in the kidney and intestines, and normally acts to regulate the levels ofsodium absorbed and secreted by the body. When administered orally, tenapanor selectively inhibits sodium uptake in the intestines, limiting the amount absorbed from food, and thereby reduces levels of sodium in the body.[6] This may make it useful in the treatment of chronic kidney disease andhypertension, both of which are exacerbated by excess sodium in the diet.[7]
It was approved for medical use in the United States in September 2019.[3][8][5][9] The U.S.Food and Drug Administration (FDA) considers it to be afirst-in-class medication.[10] In October 2023, tenapanor was approved by the FDA for the treatment ofhyperphosphatemia.[11]
This article incorporates text from this source, which is in thepublic domain. | Thisdrug article relating to thegastrointestinal system is astub. You can help Wikipedia byexpanding it. |
